Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Retained Earnings for 7 consecutive years, with -$481.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 15.3% year-over-year to -$481.8 million, compared with a TTM value of -$481.8 million through Dec 2025, up 15.3%, and an annual FY2025 reading of -$481.8 million, up 15.3% over the prior year.
  • Retained Earnings was -$481.8 million for Q4 2025 at Keros Therapeutics, down from -$458.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$80.9 million in Q1 2021 and bottomed at -$568.8 million in Q4 2024.
  • Average Retained Earnings over 5 years is -$329.5 million, with a median of -$361.3 million recorded in 2023.
  • The sharpest move saw Retained Earnings crashed 156.47% in 2021, then increased 15.3% in 2025.
  • Year by year, Retained Earnings stood at -$123.8 million in 2021, then tumbled by 84.59% to -$228.4 million in 2022, then crashed by 66.97% to -$381.4 million in 2023, then plummeted by 49.12% to -$568.8 million in 2024, then grew by 15.3% to -$481.8 million in 2025.
  • Business Quant data shows Retained Earnings for KROS at -$481.8 million in Q4 2025, -$458.3 million in Q3 2025, and -$451.0 million in Q2 2025.